An association between anti-platelet drug use and reduced cancer prevalence in diabetic patients: results from the Vermont Diabetes Information System Study

Table 1 Characteristics of 1007 study subjects

	n	*Mean*	*Range*	n	*Mean*	*Range*	P
Anti-platelet therapy	Absent			Present
Age in years	499	62.1	22.2-89.5	508	67.6	36.0-92.6	< .001
Gender: male	499	39.7%		508	51.6%		< .001
Race: white,	497	96.6%		507	98.0%		.15
Body mass index in kg/m²	492	34.5	16.1-64.6	502	33.1	15.8-68.0	.003
Glycosylated hemoglobin A1C	497	7.1%	4.0-13.5	506	7.1%	4.9-12.9	.85
More than 1 comorbid condition	499	45.1%		508	53.5%		.007
Current smoker	498	18.5%		508	15.4%		.19
Number of medications	499	7.7	0-29	508	9.8	1-29	< .001
Self-reported history of malignancy	499	13.0%		508	12.2%		.70
History of cancer	Absent			Present
Age in years	880	65.2	22.2-91.7	127	69.1	34.5-92.6	< .001
Gender: male	880	46.2%		127	41.7%		.34
Race: white,	878	97.3%		126	97.6%		.82
Body mass index in kg/m²	868	34.0	15.8-68.0	126	32.6	19.7-53.8	.05
Glycosylated hemoglobin A1C	876	7.1%	4.0-13.5	127	7.0%	4.8-13.3	.13
More than 1 comorbid condition	880	46.2%		127	71.7		< .001
Current smoker	879	17.8%		127	11.0%		.06
Number of medications	880	8.6	0-29	127	9.9	0-29	.003
Anti-platelet therapy	880	50.7%		127	48.8%		.70

ISSN: 1471-2407